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however, some small AAAs continue to expand to dimen-
sions that carry a high risk of rupture. For this reason,
patients with a small AAA are offered regular ultrasono-
graphic scans. This group of patients provides a unique
opportunity for studying the progress of the disease and its
possible association with signs of chronic C pneumoniae
infection. In 1998, the Viborg Study17 in Denmark
reported a significant correlation between IgA antibodies
and aneurysmal expansion. However, the significance was
only noticed with an IgA titer-cutpoint that was lower
than the usual titer that indicates recent or present infec-
tion. Furthermore, no correlation between titer and
expansion rate was noticed. Consequently, to confirm the
results of clinically relevant aneurysms with a longer obser-
vation period and higher expansion rate, we have studied
cases referred for surgical evaluation from the Chichester
Screening Study.
MATERIALS AND METHODS
As part of an ongoing screening program in the
Chichester area (UK) that started in 1983, more than
10,000 65- to 80-year-old men and women were invited to
undergo B-mode ultrasonographic scanning screening for
AAA.18 The attendance rate was 64%. An AAA was defined
as an aortic diameter of 30 mm or greater in the antero-
posterior or transverse plane, and 5.8% of the participants
had an AAA. Participants identified as having an aortic
diameter of 3.0 to 5.9 cm were offered follow-up examina-
An association between Chlamydia pneumoniae, ath-
erosclerosis, and the risk of acute myocardial infarction has
been shown by means of seroepidemiological studies,1-6
and C pneumoniae antigen has been detected in athero-
sclerotic lesions both from coronary and carotid arteries
and in abdominal aortic aneurysms (AAAs) in several stud-
ies.7-13 However, the culture of C pneumoniae from ath-
erosclerotic lesions has only been observed twice. Two
relatively small controlled clinical trials in which patients
with ischemic heart disease were randomized into antibi-
otic treatment or placebo groups were conducted.14,15
Both trials showed a significant reduction in serious end
points for ischemic heart disease in patients who were
receiving macrolide. It is not known whether this is caused
by the eradication of C pneumoniae organisms or by the
nonspecific anti-inflammatory effect of the macrolide.16
The relationship between infection and atherosclerotic
disease therefore remains unknown, and the clinical
importance of detecting the organism is uncertain.
Surgery is not usually recommended for small AAAs;
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Purpose: Chlamydia pneumoniae has been shown to be associated with atherosclerosis, myocardial infarction, and
abdominal aortic aneurysms (AAAs). The possible association between AAA expansion and C pneumoniae infection was
therefore assessed.
Methods: Blood samples were taken from patients with an AAA that was considered for surgical repair after having been
diagnosed by means of the Chichester aneurysm screening program (UK) as having an initially infrarenal aortic diam-
eter of 3.0 to 5.9 cm. The patients were examined prospectively for as long as 11.5 years (mean, 4.1 years) with ultra-
sound scanning. Of 110 patients considered for surgery, 90 men and 10 women had blood samples taken. Their IgG
and IgA antibodies against C pneumoniae were measured by means of a microimmunofluorescence test. Unpaired t
tests, multiple linear regression analyses, and logistic regression analyses were used for statistical analysis.
Results: A total of 44% (95% CI, 31%-55%) of the men with an AAA had an IgA titer of 64 or more, an IgG titer of
128 or more, or both, compared with 10% of the women with an AAA (OR = 7.2; 95% CI, 1.05-160.8). A titer of IgG
of 128 or more was significantly associated with higher expansion (5.3 vs 2.6 mm per year), even after adjustment for
initial AAA size and age. A significant positive correlation between both IgA and IgG titers and mean annual expan-
sion was observed (r = 0.28; 95% CI, 0.05-0.49; and r = 0.45; 95% CI, 0.24-0.62, respectively), persisting after adjust-
ing for initial AAA size and age. An IgG titer of 128 or more was present significantly more often in cases with an
expansion greater than 1 cm annually (adjusted OR = 12.6; 95% CI, 1.37-293).
Conclusion: A high proportion of men with an AAA has signs of infection with C pneumoniae. The progression of their
AAAs was positively correlated with the presence of indicators of C pneumoniae infection. (J Vasc Surg 2001;34:212-5.)
tions at 1-year or 3-month intervals, depending on the aor-
tic size, to check for any expansion. Patients with AAAs
exceeding 6 cm in diameter or expanding more than 1 cm
annually or in whom symptoms attributable to the aneurysm
developed were considered for surgery. A total of 110
patients with an AAA that was considered for surgery were
seen as outpatients. Of these, 90 men and 10 women had
IgG and IgA antibodies against C pneumoniae measured by
means of microimmunofluorescence tests.19 Ten cases were
excluded because of refusals and errors in the sampling.
Expansion was calculated as the change in the antero-
posterior diameter during the whole observation period,
transformed to annual units.
SPSS 6.1 software (SPSS Inc, Chicago, Ill) was used as
a means of performing unpaired t tests and multiple linear
regression analyses on the mean annual expansion rates,
and χ2 tests and logistic regression analyses were used as a
means of assessing annual expansion rates less or greater
than 3, 5, and 10 mm as a dependent variable.
RESULTS
The prevalence of chlamydial seropositivity in cases
varied from 10% to 44%, depending on patient sex and
type of antibodies. They are listed and compared in Table
I. The presence of infection, defined as an IgG titer of 128
or more or an IgA titer of 64 or more, was significantly
more common in men with an AAA than in women with
an AAA (OR = 7.20; 95% CI, 1.05-160.8).
For expansion, the observation time varied from 0.5
to 11.5 years (mean time, 4.1 years), and the average
annual expansion rate was 3.5 mm (range, 3-16 mm).
By means of bivariate analysis, an IgA titer of 64 or
more, an IgG titer of 128 or more, or raised IgA or IgG
titers was associated with increased mean annual expansion
and an annual expansion rate greater than 3 and 10 mm
(Table II). After adjustment for initial AAA size and age,
an IgG titer of 128 or more remained significantly associ-
ated with mean annual expansion and an annual expansion
rate greater than 3 and 10 mm (Table II).
Finally, a positive correlation between both IgA titer
and IgG titer and mean annual expansion rate was noticed
(r = 0.28; 95% CI, 0.05-0.49; and r = 0.45; 95% CI, 0.24-
0.62, respectively). This correlation remained significant
after adjustment for initial AAA size and age.
DISCUSSION
The microimmunofluorescence test is specific for the
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C pneumoniae species and allows detection of the various
immunoglobulin types against C pneumoniae. IgA anti-
body titers usually decline and disappear 3 to 12 months
after infection. An elevated level of IgA of 64 or more is
thus believed to indicate a recent or present infection.2
IgG antibodies may persist for some years.1,20-26 Only IgG
titers of 128 or more are thought to indicate recent or 
present infection.2 IgM antibodies are not detectable in
reinfections and persistent infections. Consequently, we
only measured IgA and IgG titers. We would have liked to
take repeated measurements, but this was not possible for
practical reasons.
Finally, the used titers to define recent or present
infections are unvalidated and were based on the opinions
from the experts. We are especially concerned about the
validity in diagnosing chronic infections. In an attempt to
find a better method, nested polymerase chain reaction
(PCR) identifying chlamydial DNA in monocytes in
peripheral blood has been introduced. Almost all PCR-
positive peripheral monocytes are also seropositive, but
one third of the seropositive are not PCR-positive. We do
not know which method gives the truth. It seems logical
that not all chronic infections have permanent bacteremia.
Furthermore, Dr Boman, who has taken part in the devel-
opment of nested PCR and has detected chlamydial DNA
in AAA walls, cannot find any cases with PCR-positive
peripheral monocytes among these patients with an AAA.
Consequently, we believe the definitions we used as indi-
cators of infection are currently as optimal as possible.
Similar serological identification of C pneumoniae
infection occurred in 44% of our patients with an AAA.
Saikku et al1 found that 50% of 40 men with acute
myocardial infarction and 68% of 30 men with angina pec-
toris, but only 17% of 41 matched control subjects, had
raised levels of IgG and IgA antibodies against C pneumo-
niae. The seroprevalence therefore seems to be similar to
that seen in men with an AAA.
The Viborg Study17 reported that a lower IgA titer of
32 or more was associated with aneurysmal expansion, but
the study was not able to show any positive correlation
between titers and expansion rate, nor could it demon-
strate that a titer indicating recent or present infection
with C pneumoniae was associated with expansion. Our
data have suggested that serological signs of recent or
present infection were associated with increased aneurys-
mal expansion and also demonstrated a positive correla-
tion between titers and expansion. This correlation
Table I. Chlamydia pneumoniae seropositivity among men and women with AAAs
Mean initial IgA titer IgG titer IgA titer ≥ 64 or
Mean age (y)* AAA size (mm)* ≥ 64† ≥ 128† IgG titer ≥ 128†
Men (n = 90) 70.1 (4.91) 45.4 (12.8) 22% (14%-32%) 39% (29%-49%) 44% (31%-55%)
Women (n = 10) 74.0 (5.58)‡ 56.6 (14.7)‡ 10% (0.3%-44%) 10% (0.3%-44%) 10% (0.3%-44%)
OR 2.57 (0.29-58.4) 5.73 (0.68-128.1) 7.20 (1.05-160.80)‡
*SD listed in parentheses.
†95% CI listed in parentheses.
‡P < .05.
suggests that the grade of the immunological response
plays a part in the degenerative response and that serolog-
ical monitoring could be relevant in assessing the disease
progression.
In contrast to the Viborg Study,17 our data showed
the strongest correlations between expansion and IgG; the
mean annual expansion rate was twice as high in serologi-
cally defined cases of infection with an IgG titer of 128 or
more. This remained significant after adjusting for age and
initial AAA size. This adjustment was made because the
IgG seroprevalence increases with age,27 and the most
powerful predictor of aneurysmal expansion is the initial
AAA size.18,28-32 The reason IgG was stronger than IgA
could be that the longer observation times made the per-
sistence of the IgG antibodies more relevant. In an earlier
paper, we reported the validation of our ultrasonographic
scanning measurements of the AAA diameter33; the vari-
ance of the measurements was 1 to 3 mm, which was sim-
ilar to that of other studies.28,34,35 Variation of
measurements will always diminish associations, and it
could be reduced with the use of computed tomography
scans. However, the costs of the screening program would
then have increased considerably. The observed AAAs
expanded an average of 15 mm. Consequently, the influ-
ence of the interobserver variation must have been limited.
Because of the interobserver variation and the analysis of
clinically relevant expansion, logistic regression analyses
were performed with an annual expansion rate greater
than 3 mm and more than 10 mm as dependent variables,
adjusting for age and initial AAA size. They were all sig-
nificantly dependent on a titer indicating recent or present
infection with C pneumoniae, with an adjusted OR vary-
ing from 2.8 to 12.6, except for an IgA titer of 64 or
more. This was greatest in cases with rapid expansion
higher than 1 cm annually. However, the wide CIs caused
by few numbers must be kept in mind, because it indicates
more uncertain data for this subgroup.
The Viborg Study17 could not demonstrate an associ-
ation with clinically important expansion of more than 10
mm annually.36,37 The reason our study could show such
a high OR, whereas the Viborg Study could not, is prob-
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ably because our sampling was carried out on patients con-
sidered for surgery, which includes more cases with rapid
expansion than those sampled at the initial diagnosis.
A possible explanation for the correlation between
expansion rates and chlamydial antibody titers is that men
with more severe atherosclerotic diseases have a higher
aneurysmal expansion rate, and the observed higher titers
are caused by the severe atherosclerosis.29,30,38 No
prospective studies have been able to demonstrate coexist-
ing atherosclerosis as a risk factor for expansion; the avail-
able data suggest the reverse, that lower ankle/brachial
systolic blood pressure was associated with a lower
aneurysmal expansion rate.31
We think our observations suggest that infection with
C pneumoniae may play a clinically relevant part in the
pathogenesis of AAAs.
Macrolide treatment of C pneumoniae seemed to
improve the outcome of ischemic heart disease in the 2
intervention studies aforementioned.14,15 However, the
numbers were small, and the effect may have been caused
by removal of thrombogenic risk factors with eradication
of the bacteria or by the nonspecific anti-inflammatory
and antioxidative effects of macrolide.16 Thus, the role of
C pneumoniae in the pathogenesis of atherosclerosis
remains unknown. Our results suggest that the organism
takes part in vascular degenerative processes, and
macrolide treatment should be considered in cases in
which patients are unfit for surgery while we are waiting
for the conclusions of randomized intervention trials.
Finally, large prospective studies with serological sur-
veillance including nested PCR-analysis of peripheral
blood would be interesting as a means of identifying a pri-
ori cases for surgery.
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